Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 5NETWORK 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 71Lymphoma, Large B-Cell, Diffuse 51Neoplasms 41Lymphoma, Non-Hodgkin 41Multiple Myeloma 40Lymphoma 37Recurrence 35Lymphoma, Follicular 30Carcinoma, Non-Small-Cell Lung 30Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma, B-Cell 26Triple Negative Breast Neoplasms 23Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Pancreatic Neoplasms 15Neoplasm Metastasis 15Leukemia 15Squamous Cell Carcinoma of Head and Neck 12Melanoma 12Stomach Neoplasms 11Colorectal Neoplasms 11Lymphoma, B-Cell, Marginal Zone 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, T-Cell, Peripheral 8Liposarcoma, Myxoid 8Carcinoma, Renal Cell 8Sarcoma 7

Interventions

Imatinib Mesylate 8venetoclax 6Cytarabine 5ponatinib 4nilotinib 4Azacitidine 4zosuquidar trihydrochloride 2fludarabine 2bosutinib 2RO6839921 2Decitabine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1pulrodemstat besilate 1posaconazole 1pegfilgrastim 1lestaurtinib 1gilteritinib 1flumatinib 1enasidenib 1emvododstat 1blinatumomab 1asciminib 1Whole-Body Irradiation 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1Lenalidomide 1Immunotherapy, Adoptive 1Idarubicin 1IMC-EB10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid × Cyclophosphamide × Clear all
NCT07157514 2025-09-10

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Actinium Pharmaceuticals

Phase 2/3 Not yet recruiting
306 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡